Rady Children's Hospital, University of California San Diego, 3020 Children's Way, Mail Code 5092, San Diego, CA, 92123, USA.
Coastal Pediatric Associates, Mount Pleasant, SC, USA.
Paediatr Drugs. 2022 Jul;24(4):293-305. doi: 10.1007/s40272-022-00499-x. Epub 2022 Jun 13.
Atopic dermatitis (AD) is a chronic inflammatory skin disorder that affects a substantial number of children and has a significant negative impact on affected patients and their caregivers/families. Recent studies have led to significant evolutions in the understanding of AD pathogenesis, epidemiology, and treatment. The first point of contact for many patients with new-onset AD is usually with their primary care provider or pediatrician. This underscores the importance for pediatricians to understand the basic pathophysiology and current standards of care for AD. This article provides up-to-date information and reviews the basic principles of AD pathophysiology, diagnosis, and management. In addition, the article highlights recent advances in scientific research regarding the mechanisms involved in the pathogenesis of atopic dermatitis that have resulted in the discovery of novel therapeutic targets and the development of targeted biologic therapies with the potential to revolutionize AD therapy.
特应性皮炎（AD）是一种慢性炎症性皮肤病，影响大量儿童，对患者及其照顾者/家属有重大负面影响。最近的研究使我们对 AD 的发病机制、流行病学和治疗有了重大的认识进展。许多新发 AD 患者的第一接触点通常是初级保健提供者或儿科医生。这强调了儿科医生了解 AD 的基本病理生理学和当前护理标准的重要性。本文提供了最新信息，并回顾了 AD 病理生理学、诊断和管理的基本原则。此外，本文还强调了有关特应性皮炎发病机制的机制的科学研究的最新进展，这些进展导致了新的治疗靶点的发现，并开发了靶向生物疗法，有可能彻底改变 AD 的治疗。
